Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy

= .91) compared with that of CEMRI. Conclusion This preliminary study demonstrated that CEUS (consensus interpretation) achieved sensitivity and AUC noninferior to CEMRI (one reader) in the detection of residual viable HCC following lenvatinib and anti-PD-1 antibody therapy. Chinese Clinical Trial Registry no. ChiCTR2400094263 © RSNA, 2025